<DOC>
	<DOCNO>NCT00315627</DOCNO>
	<brief_summary>The purpose study : 1 . To reverse hyperglycemia insulin dependency patient type 1 diabetes mellitus islet transplantation utilize steroid free , calcineurin-inhibitor free immunosuppression . 2 . To assess long-term function successful islet transplant patient type 1 diabetes mellitus utilize islet undergone period culture . 3 . To determine whether natural history microvascular , macrovascular , neuropathic complication alter follow successful transplantation islet .</brief_summary>
	<brief_title>Steroid-free Long-term Calcineurin-free Trial Islet Cell Transplantation</brief_title>
	<detailed_description>STUDY DESIGN : The initial proposal submit JDRFI compare 3 different group patient receive islet cell transplant utilize steroid-free , calcineurin-free protocol . The 3 group follow : 1 . Zenapax , Rapamycin &amp; MMF 2 . Campath , Rapamycin &amp; MMF , 3 . Thymoglobulin , Rapamycin &amp; MMF . The grant award December 2003 , however recommendation focus single group ( group 3 4 ) order determine relative efficacy toxicity new immunosuppressive drug combination . We elect perform group utilize Campath , since similar protocol utilize immunosuppressive regimen addition CD34+ enrich donor bone marrow cell ( 2000/0024 ) . The result trial utilizing steroid-free/calcineurin-free protocol compare standard `` Edmonton Protocol '' ( 2000/0196 ) , currently conduct ( 14 patient transplant ) . In addition , result compare 2000/0024 . Protocol 2000/0024 ( utilize immunosuppressive regimen ; Campath , Rapamycin , Tacrolimus-switched MMF 3 month ) follow DSMB establish NIH . We propose evaluate 12 patient steroid free , long term calcineurin inhibitor free immunosuppression regimens directly compare historical group patient underwent Miami version Edmonton protocol ( Islet Cell Transplantation Alone Patients Type 1 Diabetes Mellitus : Steroid-Free Immunosuppression - Protocol # 2000/196 ) concurrent tolerogenic protocol ( Islet Cell Transplantation Alone CD34+ Enriched Donor Bone Marrow Cell Infusion Patients Type 1 Diabetes Mellitus ; Steroid Free Regimen - Protocol # 2000/0024 ) use immunosuppressive regimen combine CD34+ stem cell enrich donor bone marrow infusion . The regimen consist Campath 1-H induction , maintenance immunosuppression sirolimus tacrolimus 3 month subsequent introduction mycophenolate mofetil ( MMF ) removal tacrolimus completely TNF-alpha inhibition ( etanercept ) peri-transplant period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Potential candidate must type 1 diabetes mellitus fulfill one following : 1 . Manifest sign symptom severe enough incapacitating . Incapacitating sign symptom include hypoglycemic episode require assistance others hypoglycemia unawareness ( inability recognize low blood glucose ; glucose &lt; 54 mg/dl ) . These patient high risk involvement accident ( lose consciousness act irrationally ) , thus cause harm and/or others . 2 . Patients poor diabetes control ( HbA1c &gt; 8.0 % &lt; 12 % ) , despite intensive insulin therapy , define : self monitoring blood glucose ≥ 4 times/day , multiple insulin injection ( ≥ 3/day ) insulin pump , close monitoring blood glucose control endocrinologist . These patient experience acute , rapid hyperglycemia secondary several stress factor , lead dehydration , disorientation , instance , ketoacidosis . 3 . Progressive diabetic complication . These patient chronically poor glycemic control high risk development wide variety complication ( retinopathy , neuropathy , nephropathy , cardiovascular disease ) associate diabetes . Potential candidate exclude per follow criterion : 1 . Age &lt; 18 &gt; 65 year 2 . Duration diabetes &lt; 5 year 3 . Do physician monitoring diabetes &gt; 6 month 4 . Body mass index &gt; 26 5 . Weight &gt; 80 kg 6 . Insulin requirement &gt; 1.0 u/kg/d 7 . HbA1c &gt; 12 % 8 . Stimulated basal Cpeptide &gt; 0.3 ng/ml 9 . Corrected creatinine clearance &lt; 60 ml/min 10 . Serum creatinine consistently 1.6 mg/dl 11 . Macroalbuminuria ( &gt; 300 mg/24 hour ) 12 . Anemia ( hemoglobin &lt; 12.0 g/dl male ; &lt; 11 g/dl female ) 13 . Hyperlipidemia ( fast lowdensity lipoprotein [ LDL ] cholesterol &gt; 130 mg/dl and/or fast triglyceride &gt; 200 mg/dl ) 14 . Abnormal liver function test ( consistently &gt; 1.5 x normal range ) 15 . Serological evidence HIV , HBsAg and/or HBcAb , HBsAb without history vaccination , human cell lymphotropic virus 1 ( HTLV1 ) , hepatitis C virus ( HCV ) 16 . Negative serology EpsteinBarr virus ( EBV ) evidence acute chronic infection ( IgM ≥ IgG ) 17 . Lack updated immunization per current Centers Disease Control ( CDC ) guideline ( include lack immunization hepatitis B , pneumococcus influenza season ) 18 . Presence panel reactive antibody &gt; 20 % 19 . Prostatespecific antigen ( PSA ) &gt; 4 ng/ml unless malignancy rule 20 . Positive tuberculin test ( unless proof adequate treatment latent tuberculosis provide ) 21 . Xray evidence pulmonary infection significant pathology 22 . Gall stone and/or portal hypertension and/or hemangioma liver ultrasound 23 . Abnormal abdominal pelvic ultrasound ( evidence mass consider suspicious malignancy adenopathy ) 24 . Active peptic ulcer disease 25 . Active infection 26 . Unstable cardiovascular status ( include positive stress echocardiography age &gt; 35 ) 27 . Untreated unstable proliferative diabetic retinopathy 28 . Previous/concurrent organ transplantation ( except fail islet cell pancreas transplantation ) 29 . Malignancy previous malignancy 30 . Any medical condition require chronic use steroid 31 . Active alcohol substance abuse ; smoke last 6 month . 32 . Sexually active female : postmenopausal , surgically sterile , use acceptable method contraception ( oral contraceptive , Norplant , DepoProvera , barrier device spermicide acceptable ; condom use alone acceptable ) 33 . Positive pregnancy test intent future pregnancy , male subject 's intent procreate 34 . Any condition circumstance make unsafe undergo islet cell transplant 35 . Psychogenically unable comply 36 . Failed psychological evaluation 37 . Persistent leukopenia ( white blood cell count &lt; 3,000/uL 3 occasion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Islet Transplantation</keyword>
</DOC>